• Biomarker of Early-stage Aggressive Colon Cancer

Biomarker of Early-stage Aggressive Colon Cancer

Lack of the biomarker CDX2 identifies a subgroup of patients with high-risk stage II colon cancer who appeared to benefit from adjuvant chemotherapy. These patients are usually treated with surgery alone. The findings come from a study published online January 21 in the New England Journal of Medicine. Piero Dalerba

Read more
  • Gut Microbiome Determines Efficacy of Cancer Immunotherapy

Gut Microbiome Determines Efficacy of Cancer Immunotherapy

Specific groups of intestinal microbes can boost the anti-tumor effects of cancer immunotherapies in mice, researchers show. Cancer immunotherapies that block immune inhibitory pathways have been tested in patients with several tumor types, but responses have varied. A study published in Science, while not the first to link gut microbes

Read more

It’s Not Easy to Diagnose Intermediate-Stage Liver Fibrosis

Biopsy has a low level of diagnostic performance for liver fibrosis stages F2 and F1. The recommendation for biopsy analysis, instead of non-invasive tests, for diagnosis of intermediate stages of fibrosis is therefore misleading, according to the June issue of Clinical Gastroenterology and Hepatology. Noninvasive tests such as FibroTest are

Read more

Does Mucosal Healing Determine Which Patients Will Recover From Ulcerative Colitis?

Lack of mucosal healing, based on endoscopic analysis, identifies patients with ulcerative colitis (UC) who are not likely to respond to corticosteroid therapy, according to Sandro Ardizzone et al. in the June issue of Clinical Gastroenterology and Hepatology. In a prospective study, Ardizzone et al. followed 157 patients with moderate

Read more